# Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma

> **NCT04432103** · PHASE3 · TERMINATED · sponsor: **Centro Medico ABC** · enrollment: 6 (actual)

## Conditions studied

- Covid-19

## Interventions

- **BIOLOGICAL:** Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients
- **BIOLOGICAL:** Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients

## Key facts

- **NCT ID:** NCT04432103
- **Lead sponsor:** Centro Medico ABC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-08
- **Primary completion:** 2021-01-29
- **Final completion:** 2021-01-29
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** There is new evidence that the Convalescent plasma is not useful for severe and critical COVID-19 Pneumonia
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432103, "Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04432103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*